

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ	AstraZeneca PLC
2 Reason for the notification (please tick the appropriate box or boxes):	
An acquisition or disposal of voting rights	<input checked="" type="checkbox"/>
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached	<input type="checkbox"/>
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments	<input type="checkbox"/>
An event changing the breakdown of voting rights	<input type="checkbox"/>
Other (please specify):	<input type="checkbox"/>
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	The Capital Group Companies, Inc.
4. Full name of shareholder(s) (if different from 3.): ^{iv}	See Schedule A
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	11 May 2015
6. Date on which issuer notified:	12 May 2015
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	Above 3%

8. Notified details:**A: Voting rights attached to shares** ^{viii, ix}

Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction				
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights ^x	
			Direct	Direct ^{xi}	Indirect ^{xii}	Direct	Indirect
Ordinary Shares (ISIN: GB0009895292)	32,100,333	32,100,333			32,139,533		2.544%
ADRs (ISIN: US0463531089)	5,767,760	5,767,760			5,768,891		0.457%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date ^{xiii}	Exercise/ Conversion Period ^{xiv}	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial instrument	Exercise price	Expiration date ^{xvii}	Exercise/ Conversion period ^{xviii}	Number of voting rights instrument refers to	% of voting rights ^{xix, xx}	
					Nominal	Delta

Total (A+B+C)

Number of voting rights	Percentage of voting rights
37,908,424	3.000%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^{xxi}

See Schedule A

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Martin Bennett, Assistant Company Secretary

15. Contact telephone number:

020 7604 8157

Schedule A

As of 11 May 2015

AstraZeneca PLC

	<u>Number of Shares</u>	<u>Percent of Outstanding</u>
<u>The Capital Group Companies, Inc. ("CG") holdings</u>	37,908,424	3.000%

Holdings by CG Management Companies and Funds:

Capital Guardian Trust Company	5,439,762	0.431%
Capital International Limited	165,000	0.013%
Capital International Sàrl	153,792	0.012%
Capital International, Inc.	72,300	0.006%

Capital Research and Management Company

32,077,570

2.539%